Viemed Healthcare (VMD) investor relations material

Executive summary

• Achieved record quarterly revenue of $78.1 million in Q2 2026, up 24% year-over-year and 4% sequentially, with record ventilator, PAP therapy, and sleep resupply patient counts.

• Net income attributable to shareholders was $2.8 million ($0.07 per diluted share), with Adjusted EBITDA of $13.7 million, down 4% year-over-year due to a prior-year non-recurring gain.

• Growth was driven by core ventilation, PAP therapy, sleep resupply, and maternal health service lines, supported by enhanced sales organization and operational infrastructure.

• Generated $15.9 million in operating cash flow and $8.6 million in free cash flow; repurchased over 530,000 shares for $5.1 million and repaid $2.2 million in debt.

• CEO highlighted diversified growth engines, strong cash generation, and continued investment in technology and patient care.

Financial highlights

• Q2 2026 revenue was $78.1 million (+24% YoY); gross profit was $45.0 million (57.7% margin); Adjusted EBITDA was $13.7 million (17.6% margin); net income was $2.8 million.

• Free cash flow for the quarter was $8.6 million; trailing twelve months free cash flow totaled $34.4 million.

• Cash and cash equivalents at June 30, 2026, were $10.7 million; working capital was $6.1 million.

• Net income margin for Q2 2026 was 3.5%.

• Long-term debt at quarter-end was $6.4 million, with $46 million available under credit facilities.

Outlook and guidance

• Full-year 2026 net revenue guidance raised to $314–$320 million (previously $312–$320 million); Adjusted EBITDA guidance revised to $64–$68 million (previously $65–$69 million).

• Net capital expenditures expected at 8.5%–10.0% of net revenue, lowered from previous guidance.

• Sequential revenue growth anticipated in Q3 and Q4, with Adjusted EBITDA margin expected to remain above 20%.

• Management expects continued growth through expansion of service areas, workforce, and technology investments.

• Regulatory changes, especially CMS ventilator coverage and competitive bidding reforms, may impact future reimbursement and utilization.